[Production of factor VIII preparations and their use in the substitution therapy of hemophilia A].
By means of the division of the conserved blood into cellular and plasmatic constituents it became possible to produce also plasma fractions with enriched coagulation factors. The factor-VIII-preparations got a particular importance for the substitution treatment of patients with haemophilia A, also under the viewpoint of the prophylaxis for the decrease of the frequency and the intensity of haemorrhages. Apart from the plasma fraction cryoprecipitate a preparation with a medium degree of enrichment on factor VIII could still be developed. However, with increasing enrichment the losses on factor VIII increase progressively. Despite the search for substances which substitute the factor VIII in the course of coagulation, release from the vascular wall and increase its activity, the substitution therapy with factor-VIII-preparations cannot be abandoned for the time being.
D001803:Blood Transfusion; D005169:Factor VIII / Q000302:isolation & purification / Q000627:therapeutic use*; D006467:Hemophilia A / Q000097:blood / Q000188:drug therapy*; D006801:Humans
D005169:Factor VIII
Die Herstellung von Faktor- VIII-Präparaten und deren Einsatz in der Substitutionstherapie der Hämophilie A.